Gaithersburg-based Salubris, a division of China-based Shenzhen Salubris Pharmaceuticals Co., Ltd. is currently assessing JK07 in a Phase Ib program in patients with Heart Failure with Reduced Ejection Fraction (HFrEF). In September 2022, the company announced positive interim data from the ongoing Phase 1b study of JK07 that showed the medication led to dose-dependent improvements in EF, with an average improvement of 30% observed after 90 days in one of the trial cohorts. At the time, an unblinded sentinel subject in a different cohort showed a 70% improvement from baseline after 30 days, the company reported. Topline results are expected in the first half of this year. The study demonstrated robust changes in biomarkers and exploratory efficacy parameters at dose levels that were safe and well tolerated.